Home › Incyte Announces Global License Agreement With Jiangsu Hengrui Medicine For SHR-1210, An Investigational Anti-PD-1 Monoclonal Antibody
 

Keywords :   


Incyte Announces Global License Agreement With Jiangsu Hengrui Medicine For SHR-1210, An Investigational Anti-PD-1 Monoclonal Antibody

2015-09-02 08:04:11| drugdiscoveryonline News Articles

Incyte Corporation recently announced a global license and collaboration agreement with Jiangsu Hengrui Medicine Co., Ltd. for the development and commercialization of SHR-1210, an investigational anti-PD-1 monoclonal antibody

Tags: global agreement license medicine

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
26.11Xbox360 SE
26.112004 UD Jesper Parnevik
26.11 1989 2
26.11T.A.K THE RHHHYMECITIZEN OF THE WORLD
26.11WiiU()&
26.11PA NEUMANN tlm107 BK
26.11snap on
26.110330
More »